Mode
Text Size
Log in / Sign up
N/A N=109 Other

Anesthetic Effect of Lidocaine/Epinephrine Solution Delivered Via Iontophoresis to External Auditory Apparatus

Acute Otitis Media · Chronic Otitis Media · Recurrent Acute Otitis Media

Enrolled (actual)
109
Serious AEs
0.0%
Results posted
Aug 2014
Primary outcome: Primary: Proportion of Subjects Who Achieved Anesthesia Effectiveness Per Investigator Assessment — 89.9 percentage of subjects

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Iontophoresis System (Acclarent) (Device)
Age
Pediatric, Adult, Older Adult · 0+ yrs
Sex
All
Sponsor
Integra LifeSciences Corporation
Primary completion
Jan 2011

Outcome Measures

OutcomeResultp-value
PRIMARY
Proportion of Subjects Who Achieved Anesthesia Effectiveness Per Investigator Assessment
89.9
PRIMARY
Evaluate Any Adverse Effects Associated With the Iontophoresis System (Adverse Device Effects).
1; 1
SECONDARY
Patient Tolerability of Iontophoresis Procedure Will be Measured Using a Wong Baker Faces Pain Scale
0.7
SECONDARY
Subject/Parent Reported Satisfaction With the In-office Procedure
94.3

Summary

This is a non-randomized, multicenter, prospective, clinical study intended to evaluate the effectiveness of a method for iontophoretic delivery of a buffered lidocaine/epinephrine solution for provision of tympanic membrane anesthesia in patients who are indicated for an ear procedure requiring penetration of the tympanic membrane, including, but not limited to, myringotomy, tympanocentesis with culture or tympanostomy with tube placement.

Eligibility Criteria

Inclusion Criteria

  • Age 12 months and older
  • Both male and female patients eligible
  • Patients are indicated for procedures requiring penetration of the tympanic membrane (including, but not limited to, myringotomy, tympanocentesis with culture or tympanostomy with tube implant)

Exclusion Criteria

  • Patients with a history of sensitivity or reaction to lidocaine, epinephrine or any hypersensitivity to local anesthetics of the amide type or any component of the drug solution
  • Markedly atrophic, retracted, atelectatic or perforated tympanic membrane
  • Otitis externa
  • Electrically sensitive patients and patients with electrically sensitive support systems (pacemakers, defibrillators, etc.)
  • Damaged or denuded skin in the auditory canal
  • Cerumen impaction resulting in a significant amount of cleaning required to visualize the tympanic membrane
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00941993). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search